MAIA Biotechnology (MAIA)

• Market cap: $52.9M
• 1 day: -1.71%
• 5 days: -3.37%
• 1 month: -5.49%
• 3 months: 8.86%
• 6 months: -14.00%
• Year to date: -17.70%
• 1 year: -54.62%
• 5 years: -61.43%
• 10 years: -61.43%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Employees: 13

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0% more funds holding

Funds holding: 20 [Q4 2024] → 20 (+0) [Q1 2025]

0.32% less ownership

Funds ownership: 5.32% [Q4 2024] → 4.99% (-0.32%) [Q1 2025]

18% less capital invested

Capital invested by funds: $2.75M [Q4 2024] → $2.26M (-$493K) [Q1 2025]